|Articles|June 9, 2021
Supplements and Featured Publications
- Moderate to Severe Psoriasis: Considerations for Patient Management Amid a Changing Treatment Spectrum
- Volume 27
- Issue 10
Participating Faculty for Moderate to Severe Psoriasis: Considerations for Patient Management Amid a Changing Treatment Spectrum
Author(s)Jerry Bagel, MD, MS
Advertisement
FACULTY
Jerry Bagel, MD, MS
Director
Psoriasis Treatment Center of New Jersey
East Windsor, New Jersey
Clinical Professor
Icahn School of Medicine at Mount Sinai
New York, New York
FACULTY DISCLOSURES
Jerry Bagel, MD, MS, has disclosed the following relevant commercial financial relationships or affiliations in the past 12 months:
BOARD MEMBERSHIP
The National Psoriasis Foundation, Board of Directors
CONSULTANCIES OR PAID ADVISORY BOARDS
AbbVie, Janssen Pharmaceuticals, Arcutis Biotherapeutics
GRANTS RECEIVED
AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Novartis,
Sun Pharma, UCB
LECTURE FEES FOR SPEAKING AT THE INVITATION OF A COMMERCIAL SPONSOR
AbbVie, Eli Lilly and Company, Janssen Pharmaceuticals
Articles in this issue
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers
3
Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma
4
Health Equity & Access Weekly Roundup: June 26, 2026
5

